Table 1.

Clinical and Demographic Characteristics of the CC Patient “Exploratory” Cohort and Controls Included in RNA-Seq, Microdissected Intestinal Epithelial Cell RNA-Seq, and Immunohistochemistry Analyses

Variable	Hc	auCC	itCCa	aRCC	UCb
Total number of subjects	13c	9	9	9	4
On budesonide treatment	No	No	Yes	No	No
Steroid responders	—	Yes	Yes	No	—
Female, %	53.85	77.78	77.78	100	75
Average age, y	51 (17–71)	59 (27–86)	59 (27–86)	60 (25–79)	22 (19–30)
Average stools/day	—	7.56 (6–10)	1.22 (1–2)	9.89 (4–20)	—
Average watery stools/day	—	7.56 (6–10)	0 (N/A)d	9.89 (4–20)	—
Average collagenous band, μm	—	35.00 (16–52)	28.33 (5–72)d	35.56 (10–72)	—
Average stool frequency, Mayo score	—	—	—	—	2.25 (1–3)
Average endoscopy, Mayo score	—	—	—	—	2 (1–3)

NOTE. Values are n or mean (range), unless otherwise indicated.

auCC, active/untreated collagenous colitis; aRCC, active/steroid-refractory collagenous colitis; CC, collagenous colitis; Hc, healthy control subjects; itCC, inactive/treated collagenous colitis; N/A, not applicable; RNA-seq, RNA sequencing; UC, ulcerative colitis.

^aMatched samples from itCC patients were collected before and during treatment with budesonide. Note that samples before treatment (active disease) were included in the group of auCC samples, whereas samples during treatment were included as itCC samples. One patient was not included for RNA-seq analysis of microdissected intestinal epithelial cells due to unavailability of paraffin-embedded biopsy sample.

^bUC disease extension included 1 patient with proctitis, 2 with affection of the descending colon, and 1 with pancolitis. Patients were assessed following the Mayo score. This group was only included for bulk biopsy RNA-seq analysis.

^cNine of these patients were included for intestinal epithelial cell microdissection and subsequent RNA-seq analysis.

^dNote that the average stool frequencies and collagenous band thickness before treatment of itCC patients are nearly the same as the auCC patient group.